<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04763915</url>
  </required_header>
  <id_info>
    <org_study_id>VICC SUPP 2112</org_study_id>
    <secondary_id>U01CA254832</secondary_id>
    <nct_id>NCT04763915</nct_id>
  </id_info>
  <brief_title>Improving Care After Inherited Cancer Testing</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Improving Care After Inherited Cancer Testing (IMPACT) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving&#xD;
      guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test&#xD;
      results. These interventions will be delivered to individuals with a documented&#xD;
      pathogenic/likely pathogenic (P/LP) variant or variant of uncertain significance (VUS) in an&#xD;
      inherited cancer gene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Through recruitment of a racially, geographically, and socioeconomically diverse sample of&#xD;
      patients, we will achieve the following aims:&#xD;
&#xD;
        1. Evaluate factors associated with access to genetic risk assessment, counseling, and&#xD;
           testing services&#xD;
&#xD;
        2. Conduct a randomized controlled trial to assess the effectiveness of interventions on&#xD;
           improving guideline-adherent CRM and FC of genetic test results&#xD;
&#xD;
        3. Create and pilot an adaptive intervention to tailor resources to promote CRM and FC&#xD;
&#xD;
        4. Document and compare multiple implementation outcomes across the different interventions&#xD;
           to maximize their effectiveness and improve reach to underserved populations&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FC of genetic test results (if P/LP variant result) or family history of cancer (if VUS result)</measure>
    <time_frame>12 months</time_frame>
    <description>Having at least one additional at-risk, adult, living relative who has either been told about the test result or family history of cancer by the participant or has undergone genetic testing of their own.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in CRM</measure>
    <time_frame>12 months</time_frame>
    <description>Ongoing guideline-adherent CRM or a change towards guideline-adherent CRM per National Comprehensive Cancer Network (NCCN) CRM guidelines based on genetic test results as measured by survey data and verified through medical records where possible and/or appropriate.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Inherited Cancer Syndrome</condition>
  <condition>Prostate Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GeneSHARE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Access to GeneSHARE, a web-based toolkit including interactive and narrative components to enhance FC of genetic test results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LivingLabReport</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-of-care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive standard-of-care from their treating healthcare provider.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Correlative Studies (Survey)</intervention_name>
    <description>Administer surveys</description>
    <arm_group_label>GeneSHARE</arm_group_label>
    <arm_group_label>LivingLabReport</arm_group_label>
    <arm_group_label>Standard-of-care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Correlative Studies (Interview)</intervention_name>
    <description>In-depth interviews among a subset of participants after the 12-month follow-up survey to either: 1) determine additional resources and tailored message that would be helpful; or 2) assess the adaptive intervention</description>
    <arm_group_label>GeneSHARE</arm_group_label>
    <arm_group_label>LivingLabReport</arm_group_label>
    <arm_group_label>Standard-of-care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>GeneSHARE</intervention_name>
    <description>Access to GeneSHARE, a web-based toolkit which includes interactive and narrative components to enhance FC of genetic test results.</description>
    <arm_group_label>GeneSHARE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>LivingLabReport</intervention_name>
    <description>Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.</description>
    <arm_group_label>LivingLabReport</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard-of-care &amp; Adaptive Intervention</intervention_name>
    <description>Receive standard-of-care from their treating healthcare provider. A subset of individuals will also be asked to test and pilot the adaptive intervention, which will consist of tailored resources to promote CRM and FC, after the 12-month follow-up survey.</description>
    <arm_group_label>Standard-of-care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Not adopted (i.e., have information about their biological relatives)&#xD;
&#xD;
          -  Have an email address with access to internet and a computer, tablet, or smartphone&#xD;
&#xD;
          -  Documented pathogenic/likely pathogenic variant or VUS in an inherited cancer gene&#xD;
             that has CRM guidelines listed in the National Comprehensive Cancer Network (NCCN)&#xD;
             Genetic/Familial Panel focused on Breast, Ovarian, and Pancreatic or Colorectal&#xD;
             cancers&#xD;
&#xD;
          -  Are non-adherent (i.e., either undertreatment or overtreatment) to at least one of the&#xD;
             current NCCN CRM guidelines or if currently adherent, require ongoing cancer screening&#xD;
&#xD;
          -  Have at least one at-risk adult, living relative who either:&#xD;
&#xD;
               -  has not been told about the genetic test result (if P/LP variant result) or&#xD;
                  family history of cancer (if VUS result) by the participant&#xD;
&#xD;
               -  has not had their own genetic testing if the participant has a pathogenic/likely&#xD;
                  pathogenic variant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuya Pal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann L Tezak, MA, MPH</last_name>
    <phone>615-875-2444</phone>
    <email>IMPACT@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne E Weidner, MPH</last_name>
    <phone>615-875-2444</phone>
    <email>IMPACT@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ann L Tezak, MA, MPH</last_name>
      <phone>615-875-2444</phone>
    </contact>
    <investigator>
      <last_name>Tuya Pal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Tuya Pal</investigator_full_name>
    <investigator_title>Associate Director for Cancer Health Disparities</investigator_title>
  </responsible_party>
  <keyword>Inherited Cancer Gene</keyword>
  <keyword>Pathogenic/Likely Pathogenic Variant</keyword>
  <keyword>Variant of Uncertain Significance</keyword>
  <keyword>Cancer Risk Management</keyword>
  <keyword>Family Sharing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Neoplastic Syndromes, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 18, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT04763915/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

